Hims & Hers Health (NYSE:HIMS) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of Hims & Hers Health (NYSE:HIMS - Get Free Report) in a note issued to investors on Tuesday, Marketbeat reports. The brokerage set an "overweight" rating and a $42.00 price target on the stock. Morgan Stanley's price target points to a potential upside of 34.96% from the company's previous close.

A number of other research firms have also recently weighed in on HIMS. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a report on Wednesday, November 6th. TD Cowen reissued a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. Finally, Piper Sandler restated a "neutral" rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $22.80.

Hims & Hers Health Stock Down 0.4 %

NYSE HIMS traded down $0.13 on Tuesday, hitting $31.12. The company's stock had a trading volume of 14,635,490 shares, compared to its average volume of 9,946,161. Hims & Hers Health has a 1-year low of $8.09 and a 1-year high of $35.02. The company's 50-day moving average is $25.02 and its 200 day moving average is $21.06. The firm has a market cap of $6.80 billion, a PE ratio of 70.09 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. During the same period last year, the company posted ($0.04) earnings per share. The business's quarterly revenue was up 77.1% on a year-over-year basis. On average, equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the company's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the sale, the insider now owns 184,947 shares of the company's stock, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total value of $47,738.99. Following the sale, the insider now owns 172,274 shares of the company's stock, valued at approximately $3,516,112.34. This represents a 1.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,064,976 shares of company stock worth $25,396,895. 17.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Main Management ETF Advisors LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth $672,000. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Hims & Hers Health in the third quarter valued at $604,000. Carnegie Investment Counsel acquired a new stake in shares of Hims & Hers Health in the third quarter valued at $5,531,000. Royce & Associates LP lifted its holdings in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company's stock valued at $6,281,000 after buying an additional 49,500 shares during the period. Finally, Versor Investments LP acquired a new stake in shares of Hims & Hers Health in the third quarter valued at $634,000. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.